Development of a method to increase power in economic analyses of multinational trials

被引：0
|
作者：
Friedman, J
Weinfurt, K
Curtis, L
Gnanasakthy, A
Schulman, K
机构：
[1] Duke Clin Res Inst, Durham, NC USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
CIRCULATION | 2002年 / 106卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P167
引用
收藏
页码：E105 / E106
页数：2
相关论文
共 50 条
  • [1] Economic analysis of multinational clinical trials in oncology
    Lejeune, Catherine
    Lueza, Beranger
    Bonastre, Julia
    BULLETIN DU CANCER, 2018, 105 (02) : 204 - 211
  • [2] The Multinational Nature of Cost-Effectiveness Analyses Alongside Multinational Clinical Trials
    Rivero-Arias, Oliver
    Gray, Alastair
    VALUE IN HEALTH, 2010, 13 (01) : 34 - 41
  • [3] MULTINATIONAL CORPORATION AND WORLD ECONOMIC DEVELOPMENT
    KATZENBA.ND
    BEHRMAN, JN
    GRANT, JP
    EBB, LF
    STOBAUGH, RB
    MALMGREN, HB
    AMERICAN JOURNAL OF INTERNATIONAL LAW, 1972, 66 (04) : 14 - 22
  • [4] MULTINATIONAL FIRMS AND AFRICAN ECONOMIC DEVELOPMENT
    BANKS, FE
    JOURNAL OF WORLD TRADE, 1975, 9 (03) : 347 - 354
  • [5] Analytic considerations in economic evaluations of multinational cardiovascular clinical trials
    Torti, Frank M., Jr.
    Reed, Shelby D.
    Schulman, Kevin A.
    VALUE IN HEALTH, 2006, 9 (05) : 281 - 291
  • [6] Increase in power through multivariate analyses
    Schmitz, S
    Cherny, SS
    Fulker, DW
    BEHAVIOR GENETICS, 1998, 28 (05) : 357 - 363
  • [7] Increase in Power through Multivariate Analyses
    Stephanie Schmitz
    Stacey S. Cherny
    David W. Fulker
    Behavior Genetics, 1998, 28 : 357 - 363
  • [8] Revisiting the impact of multinational enterprises on economic development
    Ghauri, Pervez N.
    Yamin, Mo
    JOURNAL OF WORLD BUSINESS, 2009, 44 (02) : 105 - 107
  • [9] Economic analyses: New endpoints for clinical trials
    Konski, A
    Grigsby, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (04): : 847 - 848
  • [10] Publication Bias in Clinical Trials and Economic Analyses
    Nick Freemantle
    James Mason
    PharmacoEconomics, 1997, 12 : 10 - 16
12345